Search - tctmd.com

Displaying 41 - 60 of 436

Sort: Relevancy | Date

Peridevice Leaks After LAA Occlusion Signal Poorer 5-Year Outcomes

News Daily News

Peridevice Leaks After LAA Occlusion Signal Poorer 5-Year Outcomes

July 28, 2022

Desperate for Relief, Long COVID Patients Seek Apheresis, Other Untested Therapies

News Daily News

Desperate for Relief, Long COVID Patients Seek Apheresis, Other Untested Therapies

July 14, 2022

LAA Occlusion With Watchman Provides Good Early Results in China

News Daily News

LAA Occlusion With Watchman Provides Good Early Results in China

June 07, 2022

Subclinical Thrombosis After TAVI Benign, at Least to 3 Years

News Daily News

Subclinical Thrombosis After TAVI Benign, at Least to 3 Years

Michael O'Riordan

June 07, 2022

The Hunt for Protein Culprits in COVID-19’s Cardiac Complications

News Daily News

The Hunt for Protein Culprits in COVID-19’s Cardiac Complications

Michael O'Riordan

May 06, 2022

NCDR Analyses Offer Insights Into First-Generation Watchman Outcomes

News Daily News

NCDR Analyses Offer Insights Into First-Generation Watchman Outcomes

May 03, 2022

Statin Use, at Any Dose, Not Linked to Excess Dementia Risk in FH

News Daily News

Statin Use, at Any Dose, Not Linked to Excess Dementia Risk in FH

Yael L. Maxwell

April 22, 2022

Early Aspirin Tied to Less In-Hospital Mortality in Moderate COVID-19

News Daily News

Early Aspirin Tied to Less In-Hospital Mortality in Moderate COVID-19

March 25, 2022

REMAP-CAP: Mixed Results for Antiplatelets in Critical COVID-19

News Daily News

REMAP-CAP: Mixed Results for Antiplatelets in Critical COVID-19

March 22, 2022

Antithrombotics Not Worth the Risk During Endovascular Stroke Therapy

News Daily News

Antithrombotics Not Worth the Risk During Endovascular Stroke Therapy

March 07, 2022

Shorter Anticoagulation an Option for Young Patients With Provoked VTE

News Daily News

Shorter Anticoagulation an Option for Young Patients With Provoked VTE

January 11, 2022

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

News Daily News

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

January 10, 2022

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

News Daily News

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

December 29, 2021

FDA Approves Two Additional Indications for Rivaroxaban in Children

News Daily News

FDA Approves Two Additional Indications for Rivaroxaban in Children

December 21, 2021

PASCAL Pinpoints Patients With Strokes Causally Related to PFO

News Daily News

PASCAL Pinpoints Patients With Strokes Causally Related to PFO

Yael L. Maxwell

December 20, 2021

Select COVID-19 Patients May Benefit From Postdischarge Anticoagulation

News Daily News

Select COVID-19 Patients May Benefit From Postdischarge Anticoagulation

November 25, 2021

Tendyne at 2 Years: Confirmed Feasibility but High Mortality With TMVR

News Daily News

Tendyne at 2 Years: Confirmed Feasibility but High Mortality With TMVR

Yael L. Maxwell

November 03, 2021

Half-Dose DOAC May Be a Good Post-Watchman Option

News Daily News

Half-Dose DOAC May Be a Good Post-Watchman Option

October 14, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

COVID-19: TCTMD’s Dispatch for October Week 2

News Daily News

COVID-19: TCTMD’s Dispatch for October Week 2

October 11, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.